Physician profile
Michael Timar
NPI 1477042968
$1,387.67
in general payments reported to CMS, 2019-2025
24 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.29 · 2020: $224 · 2021: $17.32 · 2022: $59.68 · 2023: $318 · 2024: $345 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209.76 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $182.32 | 2023-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $137.92 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $136.49 | 2023-2025 | |
| Exact Sciences Corporation | $90.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $85.36 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $79.46 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $64.23 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $51.93 | 2024-2025 | Repatha, Otezla, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $45.59 | 2023-2025 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $36.19 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $35.00 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $32.94 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Otsuka America Pharmaceutical, INC. | $22.88 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $21.01 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $21.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.24 | 2024 | Voquezna |
| Abbott Laboratories | $18.62 | 2025 | Freestyle Libre 2 |
| Lundbeck LLC | $17.73 | 2025 | Rexulti |
| Agios Pharmaceuticals, INC. | $17.71 | 2025 | Pyrukynd |
| Biohaven Pharmaceuticals, INC. | $17.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.53 | 2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $14.50 | 2024 | Contrave |
| Sanofi Pasteur INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Timar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.